Recent clinical studies revealed that a minor percentage of diffuse large B cell lymphoma (DLBCL) patients had tumor cells with CD30 expression (Hu et al., 2013). This evidence concerns the gene TNFRSF8 and diffuse large B-cell lymphoma.